European heart journal
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.
Kai Zhang, Alyssa Ayala, Ignacio Norambuena-Soto, Vertica Agnihotri, Tao Shu, Christian Nenninger, Yin Wang, Brittany Echevarria, Joel Aboagye, Katie Huang, Jenaro Espitia-Corredor, Xiwei Wu, Zhen B Chen, Yingfeng Deng, J Jefferson P Perry
Published: 202510.1093/eurheartj/ehaf813
Abstract
BACKGROUND AND AIMS: Osimertinib is a third-generation tyrosine kinase inhibitor targeting activating mutations of epidermal growth factor receptor with remarkable therapeutic efficacy against non-small cell lung carcinoma. However, its use has been…
Preview only. Read the full abstract at the source